Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
Plain-language summary
This is a research study collecting clinical information and/or biological samples from patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Brentuximab Vedotin Plus CHP (DRUG): Brentuximab vedotin administered in combination with cyclophosphamide, doxorubicin, and prednisone (BV-CHP) as first-line treatment according to routine clinical practice. The treatment was prescribed by the treating physician as part of standard medical care and was not assigned or modified by the study
Brentuximab Vedotin Plus CHP
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details